Altogether, these results indicate that targeting PRDX2 in hepatocytes prevents HCC development in MASH by (a) improving metabolic liver disease and (b) suppressing procarcinogenic signaling pathways. Here, PRDX2 is linked to metabolic dysfunction-associated steatohepatitis.